Details of the Drug Combination

General Information of Drug Combination (ID: DCNNSIO)

Drug Combination Name

BMS-754807 Ixazomib

Indication

Disease Entry	Status	REF
Diffuse intrinsic pontine glioma	Investigative	[1]

Component Drugs

BMS-754807 DMPK32V

Ixazomib DM5ZVLB

Small molecular drug

N.A.

2D MOL

3D MOL

3D MOL is unavailable

High-throughput Screening Result

Testing Cell Line: DIPG25

Zero Interaction Potency (ZIP) Score: 9.756

Bliss Independence Score: 9.754

Loewe Additivity Score: 5.169

LHighest Single Agent (HSA) Score: 8.121

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

BMS-754807 Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
RAC-alpha serine/threonine-protein kinase (AKT1)	TTWTSCV	AKT1_HUMAN	Inhibitor	[3]
------------------------------------------------------------------------------------

BMS-754807 Interacts with 2 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Cyclin-dependent kinase inhibitor 2A (CDKN2A)	OTN0ZWAE	CDN2A_HUMAN	Decreases Response To Substance	[4]
Retinoblastoma-associated protein (RB1)	OTQJUJMZ	RB_HUMAN	Decreases Response To Substance	[4]
------------------------------------------------------------------------------------

Indication(s) of Ixazomib

Disease Entry	ICD 11	Status	REF
Multiple myeloma	2A83	Approved	[2]

References

1	CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2015
3	Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in cli... J Med Chem. 2009 Dec 10;52(23):7360-3.
4	CDK4/6 and IGF1 receptor inhibitors synergize to suppress the growth of p16INK4A-deficient pancreatic cancers. Cancer Res. 2014 Jul 15;74(14):3947-58. doi: 10.1158/0008-5472.CAN-13-2923. Epub 2014 Jul 1.